[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637682":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":41,"responsibleParty":67,"collaborators":11,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":11,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":11,"enrollmentInfo":78,"targetDuration":11,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Greater Atlanta Integrative Pediatrics","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Glutathione with Stem Cells","EXPERIMENTAL",null,[13,14],"Biological: Umbilical Cord Blood-Derived Stem Cells and Exosomes","Drug: Glutathione",{"label":16,"type":17,"description":11,"interventionNames":18},"Glutathione Only","ACTIVE_COMPARATOR",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"BIOLOGICAL","Umbilical Cord Blood-Derived Stem Cells and Exosomes","Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem\u002Fstromal cells) and exosomes.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","Glutathione","Reduced L-glutathione administered Intravenous infusion once monthly for 3 months (Initial Treatment Schedule)",[16,9],[31],{"name":32,"affiliation":5,"role":33},"Maia Gaither, MD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":11,"email":38},"CONTACT","4047513693","intakes@gaipeds.com",{"name":40,"role":36,"phone":37,"phoneExt":11,"email":38},"Amy Westmoreland, MSN",[42,60],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Roswell","Georgia","30076","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-84.36159,34.02316,{"lat":53,"lon":52},[56,58,59],{"name":32,"role":36,"phone":37,"phoneExt":11,"email":57},"heal@gaipeds.com",{"name":40,"role":36,"phone":37,"phoneExt":11,"email":38},{"name":32,"role":33,"phone":11,"phoneExt":11,"email":11},{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},{"type":50,"coordinates":62},[52,53],{"lat":53,"lon":52},[65,66],{"name":32,"role":36,"phone":11,"phoneExt":11,"email":38},{"name":11,"role":36,"phone":37,"phoneExt":11,"email":11},{"type":68,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100637682","phase-1-gaip-asd-research-study-100637682",false,"NCT07622316","GAIP ASD Research Study","Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder Research Study","Inclusion Criteria:\n\n* Age 3 years and up\n* Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2 or its equivalent)\n* Parent\u002Fguardian willingness to consider experimental treatments and comply with study requirements\n* Ability to obtain required bloodwork\n* Ability to attend all scheduled visits\n\nExclusion Criteria:\n\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Immunocompromised\n* Malignancy history\n* Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days","ALL","3 Years",{"count":79,"type":80},100,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","This clinical research study evaluates the safety and preliminary effects of AdiaVita (umbilical cord blood-derived stem cells and exosomes) combined with glutathione versus glutathione alone in people aged 3 and older with Autism Spectrum Disorder (ASD). In this randomized, participant-blinded crossover trial of about 100 participants, one group receives three monthly AdiaVita IV infusions plus glutathione, while the control group gets placebo saline infusions with the same glutathione regimen; the primary outcome is improvement on Autism Treatment Evaluation Checklist (ATEC) scores, with full safety follow-up through 12 months and optional crossover to AdiaVita for eligible controls. The treatment is investigational and not FDA-approved for autism, with no guaranteed benefit and risks including infusion reactions; participants pay $12,000 for the initial schedule, and all data remains confidential.",[86,87,88,89],"Autism Spectrum Disorder","Autism","ASD","Autism Spectrum Disorder (ASD)",[27,91,92,93,94,95,96,87,86,88,97,98,99,100,101],"Intravenous glutathione","Glutathione therapy","Antioxidant therapy","Oxidative stress","Immune modulation","Anti-inflammatory therapy","Autism symptoms","Stem cell therapy","Regenerative medicine","Allogeneic stem cells","Cellular therapy","2026-06-01",{"date":104,"type":105},"2026-06-03","ACTUAL",{"date":102,"type":80},{"date":108,"type":80},"2027-06-30",{"name":5,"class":6},2]